See more : Lojas Renner S.A. (LREN3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Haemonetics Corporation (HAE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Haemonetics Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Arctic Fish Holding AS (AFISH.OL) Income Statement Analysis – Financial Results
- Vishnu Chemicals Limited (VISHNU.BO) Income Statement Analysis – Financial Results
- Nestbuilder.com Corp. (NBLD) Income Statement Analysis – Financial Results
- PT Jaya Swarasa Agung Tbk (TAYS.JK) Income Statement Analysis – Financial Results
- Immobiliere Distri-Land NV (DISL.BR) Income Statement Analysis – Financial Results
Haemonetics Corporation (HAE)
About Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.31B | 1.17B | 993.20M | 870.46M | 988.48M | 967.58M | 903.92M | 886.12M | 909.68M | 910.37M | 938.51M | 891.99M | 727.84M | 676.69M | 645.43M | 597.88M | 516.44M | 449.61M | 419.73M | 383.60M | 364.23M | 336.96M | 319.97M | 293.86M | 277.92M | 282.10M | 285.80M | 309.80M | 278.20M | 262.40M | 248.40M | 216.30M | 176.40M | 157.30M |
| Cost of Revenue | 617.51M | 553.56M | 487.69M | 472.63M | 503.97M | 550.04M | 492.02M | 507.62M | 503.80M | 475.96M | 470.14M | 463.86M | 358.60M | 321.49M | 307.95M | 289.71M | 258.72M | 222.31M | 199.20M | 185.72M | 192.11M | 182.26M | 165.14M | 126.95M | 121.70M | 124.00M | 127.10M | 137.80M | 110.50M | 103.90M | 94.20M | 88.80M | 78.50M | 0.00 |
| Gross Profit | 691.55M | 615.10M | 505.50M | 397.84M | 484.51M | 417.54M | 411.91M | 378.49M | 405.87M | 434.42M | 468.37M | 428.13M | 369.24M | 355.21M | 337.48M | 308.17M | 257.73M | 227.30M | 220.54M | 197.88M | 172.12M | 154.70M | 154.83M | 166.91M | 156.22M | 158.10M | 158.70M | 172.00M | 167.70M | 158.50M | 154.20M | 127.50M | 97.90M | 157.30M |
| Gross Profit Ratio | 52.83% | 52.63% | 50.90% | 45.70% | 49.02% | 43.15% | 45.57% | 42.71% | 44.62% | 47.72% | 49.91% | 48.00% | 50.73% | 52.49% | 52.29% | 51.54% | 49.90% | 50.56% | 52.54% | 51.58% | 47.26% | 45.91% | 48.39% | 56.80% | 56.21% | 56.04% | 55.53% | 55.52% | 60.28% | 60.40% | 62.08% | 58.95% | 55.50% | 100.00% |
| Research & Development | 54.44M | 50.13M | 46.80M | 32.86M | 30.88M | 35.71M | 39.23M | 37.56M | 45.57M | 54.19M | 54.20M | 48.64M | 36.80M | 32.66M | 26.38M | 23.86M | 24.32M | 23.88M | 26.52M | 19.99M | 17.79M | 19.51M | 19.51M | 19.04M | 14.93M | 15.10M | 17.90M | 19.00M | 18.50M | 16.70M | 15.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 424.68M | 369.48M | 335.16M | 271.49M | 295.38M | 293.78M | 313.42M | 299.23M | 320.07M | 335.19M | 363.24M | 314.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.10M | 7.20M | 4.40M | 2.70M | 4.30M | 4.50M | 3.10M | 2.50M | 3.90M | 4.50M | 3.60M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 431.78M | 376.68M | 339.56M | 274.19M | 299.68M | 298.28M | 316.52M | 301.73M | 323.97M | 339.69M | 366.84M | 318.81M | 245.26M | 213.90M | 214.48M | 198.74M | 163.12M | 137.07M | 121.35M | 118.04M | 108.45M | 97.71M | 88.87M | 86.73M | 82.76M | 86.70M | 86.90M | 92.30M | 81.80M | 75.70M | 75.90M | 77.20M | 61.00M | 0.00 |
| Other Expenses | 40.45M | 32.26M | 47.41M | 32.83M | 50.60M | 0.00 | 0.00 | -8.10M | 87.67M | 5.44M | 1.71M | -6.54M | 0.00 | -1.89M | 13.34M | 0.00 | 0.00 | -5.48M | -26.35M | -100.00K | 0.00 | 0.00 | 0.00 | 4.61M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| Operating Expenses | 526.67M | 459.06M | 433.78M | 339.88M | 330.56M | 333.99M | 355.75M | 339.28M | 369.54M | 393.88M | 421.04M | 367.45M | 282.06M | 244.66M | 240.86M | 222.60M | 187.44M | 155.48M | 121.52M | 137.93M | 126.24M | 117.22M | 108.39M | 110.39M | 122.59M | 126.40M | 127.70M | 123.60M | 113.40M | 106.10M | 102.40M | 85.70M | 68.00M | 0.00 |
| Cost & Expenses | 1.14B | 459.06M | 921.47M | 812.50M | 834.53M | 884.03M | 847.77M | 846.90M | 873.34M | 869.83M | 891.18M | 831.31M | 640.67M | 566.15M | 548.81M | 512.31M | 446.15M | 377.79M | 320.72M | 323.66M | 318.35M | 299.48M | 273.52M | 237.34M | 244.29M | 250.40M | 254.80M | 261.40M | 223.90M | 210.00M | 196.60M | 174.50M | 146.50M | 0.00 |
| Interest Income | 0.00 | 13.00M | 5.80M | 9.40M | 13.50M | 9.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 384.00K | 399.00K | 1.97M | 0.00 | 7.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.02M | 14.63M | 17.12M | 16.83M | 16.20M | 9.91M | 4.53M | 8.10M | 9.47M | 9.38M | 10.93M | 6.54M | 0.00 | 6.00K | 742.00K | 64.00K | 0.00 | 97.00K | 0.00 | 0.00 | 0.00 | 0.00 | 13.58M | 59.39M | 13.10M | 0.00 | 74.90M | 0.00 | 0.00 | 0.00 | 0.00 | 1.60M | 1.60M | 0.00 |
| Depreciation & Amortization | 97.22M | 93.31M | 97.75M | 84.29M | 110.29M | 109.42M | 89.25M | 89.73M | 89.91M | 86.05M | 81.74M | 65.48M | 49.97M | 48.15M | 43.24M | 36.46M | 31.20M | 27.50M | 25.15M | 27.58M | 30.15M | 28.43M | 25.62M | 24.50M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| EBITDA | 265.58M | 249.34M | 178.50M | 142.25M | 264.24M | 192.96M | 153.03M | 70.35M | 45.97M | 125.72M | 127.04M | 124.58M | 139.46M | 158.23M | 125.25M | 121.53M | 101.48M | 101.10M | 124.17M | 87.52M | 77.44M | 65.91M | 72.06M | 81.02M | 73.13M | 51.20M | 53.90M | 72.00M | 67.40M | 66.10M | 62.50M | 50.30M | 36.90M | 157.30M |
| EBITDA Ratio | 20.29% | 21.34% | 17.06% | 16.34% | 26.73% | 19.94% | 16.09% | 14.55% | 13.89% | 4.45% | 5.04% | 6.80% | 11.66% | 23.51% | 15.03% | 20.74% | 19.27% | 22.23% | 22.63% | 22.78% | 20.60% | 18.85% | 25.00% | 34.44% | 23.56% | 18.15% | 26.91% | 18.30% | 23.08% | 24.43% | 24.07% | 23.16% | 20.58% | 100.00% |
| Operating Income | 164.88M | 156.03M | 80.75M | 57.96M | 153.95M | 83.55M | 56.16M | -19.38M | -43.98M | 40.54M | 47.33M | 56.44M | 88.76M | 110.55M | 83.28M | 85.57M | 70.29M | 62.75M | 99.02M | 59.94M | 45.88M | 37.48M | 36.45M | 13.42M | 33.63M | 31.70M | 31.00M | 48.40M | 54.30M | 52.40M | 51.80M | 41.80M | 29.90M | 157.30M |
| Operating Income Ratio | 12.60% | 13.35% | 8.13% | 6.66% | 15.57% | 8.63% | 6.21% | -2.19% | -4.84% | 4.45% | 5.04% | 6.33% | 12.19% | 16.34% | 12.90% | 14.31% | 13.61% | 13.96% | 23.59% | 15.63% | 12.60% | 11.12% | 11.39% | 4.57% | 12.10% | 11.24% | 10.85% | 15.62% | 19.52% | 19.97% | 20.85% | 19.33% | 16.95% | 100.00% |
| Total Other Income/Expenses | -13.02M | -14.63M | -17.12M | 14.95M | -16.20M | -9.91M | 3.48M | -8.10M | -97.14M | -9.38M | -10.93M | -6.54M | 740.00K | -467.00K | -2.01M | -565.00K | 7.02M | 9.59M | 7.86M | -102.00K | -65.00K | 1.13M | 2.06M | 3.91M | 3.25M | 969.00K | -26.50M | 2.30M | 900.00K | 100.00K | -1.00M | -1.80M | -2.20M | -157.30M |
| Income Before Tax | 151.87M | 141.40M | 63.63M | 72.91M | 87.15M | 73.63M | 59.63M | -27.48M | -53.46M | 31.17M | 36.40M | 49.90M | 89.50M | 110.08M | 81.27M | 85.00M | 77.30M | 72.34M | 106.88M | 59.84M | 45.81M | 38.61M | 38.51M | 17.33M | 27.33M | 32.60M | 4.50M | 50.70M | 55.20M | 52.50M | 50.80M | 40.00M | 27.70M | 0.00 |
| Income Before Tax Ratio | 11.60% | 12.10% | 6.41% | 8.38% | 8.82% | 7.61% | 6.60% | -3.10% | -5.88% | 3.42% | 3.88% | 5.59% | 12.30% | 16.27% | 12.59% | 14.22% | 14.97% | 16.09% | 25.46% | 15.60% | 12.58% | 11.46% | 12.03% | 5.90% | 9.83% | 11.56% | 1.57% | 16.37% | 19.84% | 20.01% | 20.45% | 18.49% | 15.70% | 0.00% |
| Income Tax Expense | 34.31M | 26.00M | 20.25M | -6.56M | 10.63M | 18.61M | 14.06M | -1.21M | 2.16M | 14.27M | 1.25M | 11.10M | 22.61M | 30.10M | 22.90M | 25.70M | 25.32M | 23.23M | 37.81M | 20.20M | 16.49M | 10.23M | 10.78M | 10.09M | 8.47M | 11.40M | 3.90M | 17.70M | 19.30M | 18.90M | 19.30M | 15.20M | 9.70M | 0.00 |
| Net Income | 117.56M | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M | 45.57M | -26.27M | -55.62M | 16.90M | 35.15M | 38.80M | 66.89M | 79.98M | 58.38M | 59.30M | 51.98M | 49.11M | 69.08M | 39.64M | 29.32M | 28.38M | 30.03M | 7.24M | 19.00M | 21.10M | -24.80M | 33.00M | 35.90M | 33.60M | 31.50M | 24.80M | 18.00M | 0.00 |
| Net Income Ratio | 8.98% | 9.87% | 4.37% | 9.13% | 7.74% | 5.69% | 5.04% | -2.96% | -6.11% | 1.86% | 3.75% | 4.35% | 9.19% | 11.82% | 9.04% | 9.92% | 10.07% | 10.92% | 16.46% | 10.33% | 8.05% | 8.42% | 9.38% | 2.46% | 6.84% | 7.48% | -8.68% | 10.65% | 12.90% | 12.80% | 12.68% | 11.47% | 10.20% | 0.00% |
| EPS | 2.32 | 2.27 | 0.85 | 1.57 | 1.51 | 1.07 | 0.86 | -0.51 | -1.09 | 0.33 | 0.68 | 0.76 | 1.30 | 1.59 | 1.15 | 1.17 | 1.00 | 0.92 | 1.29 | 0.77 | 0.60 | 0.57 | 0.57 | 0.14 | 0.30 | 0.39 | -0.47 | 0.61 | 0.66 | 0.61 | 0.56 | 0.45 | 0.33 | 0.26 |
| EPS Diluted | 2.29 | 2.24 | 0.84 | 1.55 | 1.48 | 1.04 | 0.85 | -0.51 | -1.09 | 0.32 | 0.67 | 0.74 | 1.30 | 1.56 | 1.12 | 1.14 | 0.97 | 0.89 | 1.25 | 0.75 | 0.60 | 0.56 | 0.56 | 0.14 | 0.29 | 0.39 | -0.47 | 0.60 | 0.65 | 0.59 | 0.55 | 0.44 | 0.32 | 0.25 |
| Weighted Avg Shares Out | 50.71M | 50.78M | 51.05M | 50.69M | 50.69M | 51.53M | 52.76M | 51.51M | 50.91M | 51.53M | 51.61M | 51.35M | 50.73M | 50.15M | 50.90M | 50.78M | 51.65M | 53.49M | 52.96M | 51.05M | 48.87M | 49.18M | 52.43M | 50.60M | 52.17M | 53.49M | 52.77M | 54.38M | 54.39M | 55.54M | 55.75M | 55.73M | 55.38M | 55.60M |
| Weighted Avg Shares Out (Dil) | 51.40M | 51.42M | 51.35M | 51.29M | 51.82M | 52.94M | 53.50M | 51.52M | 50.91M | 52.09M | 52.38M | 52.26M | 51.59M | 51.19M | 52.13M | 52.35M | 53.49M | 55.30M | 54.95M | 52.85M | 49.28M | 50.10M | 54.31M | 52.01M | 53.00M | 53.77M | 53.33M | 54.83M | 55.23M | 56.95M | 57.80M | 57.01M | 57.14M | 55.60M |
Top Medical Stocks to Buy for Growth & Performance
The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.
Wall Street Analysts Think Haemonetics (HAE) Could Surge 33.2%: Read This Before Placing a Bet
The consensus price target hints at a 33.2% upside potential for Haemonetics (HAE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
5 Well-Positioned Relative Price Strength Stocks to Buy Now
NEP, TREE, HAE, CTRA and WSM are five stocks with explosive relative price strength.
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024
BOSTON , July 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, August 8, 2024. The Company will hold a conference...
Haemonetics (HAE) Loses -5.16% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is...
Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to enter...
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.
4 Medical Product Stocks to Buy From a Recovering Industry
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device
BOSTON , June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure...
HAE vs. BSX: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Source: https://incomestatements.info
Category: Stock Reports